Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.58
-13.8%
$0.56
$0.16
$0.82
$617.62M0.241.23 million shs4.45 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$44.82
+0.9%
$37.73
$19.45
$53.27
$2.92B2.18629,535 shs482,080 shs
Metsera Inc. stock logo
MTSR
Metsera
$28.71
+6.8%
$26.98
$12.30
$37.99
$3.02BN/A916,922 shs807,525 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$35.42
+4.9%
$32.27
$6.76
$46.98
$3.21B0.331.29 million shs563,354 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
-8.33%-13.40%+24.49%+66.17%+235.67%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
+1.83%-5.73%+50.85%+68.59%+43.59%
Metsera Inc. stock logo
MTSR
Metsera
-5.52%-8.29%+1.40%+18.62%+2,687,999,900.00%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-4.69%+1.05%+15.89%+3.75%+315.25%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.3782 of 5 stars
0.03.00.00.02.20.80.0
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.1035 of 5 stars
4.51.00.00.03.02.50.0
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.5634 of 5 stars
2.60.00.04.42.43.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00
N/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.00
Buy$59.6133.00% Upside
Metsera Inc. stock logo
MTSR
Metsera
3.00
Buy$55.0091.57% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.14
Buy$42.6720.48% Upside

Current Analyst Ratings Breakdown

Latest ELTP, SRRK, MTSR, and KYMR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$56.00 ➝ $53.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$59.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$57.00 ➝ $53.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $60.00
6/25/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$64.00
6/20/2025
Metsera Inc. stock logo
MTSR
Metsera
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$65.00
6/18/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$50.00
6/10/2025
Metsera Inc. stock logo
MTSR
Metsera
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$56.00 ➝ $62.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$57.00 ➝ $64.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$38.00 ➝ $60.00
(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$84.04M7.35$0.02 per share24.95$0.05 per share11.56
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$47.07M62.01N/AN/A$12.90 per share3.47
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/A($2.46) per shareN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/A$3.94 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$20.11M-$0.02N/AN/A-25.70%-6.92%-3.94%8/14/2025 (Estimated)
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)
Metsera Inc. stock logo
MTSR
Metsera
-$209.13MN/A0.00N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$246.29M-$2.53N/AN/AN/AN/A-118.22%-82.01%8/6/2025 (Estimated)

Latest ELTP, SRRK, MTSR, and KYMR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/30/2025Q4 2025
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/A$0.01N/A$0.02N/A$32.00 million
5/14/2025Q1 2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.63-$0.67-$0.04-$0.67N/AN/A
5/12/2025Q1 2025
Metsera Inc. stock logo
MTSR
Metsera
N/A-$1.03N/A-$1.03N/AN/A
5/9/2025Q1 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.12
3.27
1.90
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
8.49
8.49
Metsera Inc. stock logo
MTSR
Metsera
N/A
6.55
6.55
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.16
10.25
10.25

Institutional Ownership

CompanyInstitutional Ownership
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.01%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
Metsera Inc. stock logo
MTSR
Metsera
N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%

Insider Ownership

CompanyInsider Ownership
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
14.42%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
16.01%
Metsera Inc. stock logo
MTSR
Metsera
N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
13.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
401.07 billion914.31 millionNot Optionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17065.12 million54.69 millionOptionable
Metsera Inc. stock logo
MTSR
Metsera
81105.06 millionN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
14094.95 million82.32 millionOptionable

Recent News About These Companies

Scholar Rock: EMBRAZE Results Drive The Stock Higher
Scholar Rock (NASDAQ:SRRK) Trading Down 5.7% - Time to Sell?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Elite Pharmaceuticals stock logo

Elite Pharmaceuticals OTCMKTS:ELTP

$0.58 -0.09 (-13.85%)
As of 02:35 PM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$44.82 +0.38 (+0.86%)
As of 03:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Metsera stock logo

Metsera NASDAQ:MTSR

$28.71 +1.83 (+6.81%)
As of 03:01 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$35.42 +1.66 (+4.90%)
As of 03:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.